Accessibility Menu
Botanix Pharmaceuticals logo

Botanix Pharmaceuticals(OTC) BXPHF

Market Cap$45.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-92%
5 Year-76%
1 Year-83%
1 Month+29%
$0.02
-25.33%
-0.01Today
Botanix Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.022026-08-18
Botanix Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+12%USD 0.022026-07-31
1 month+29.23%USD 0.012026-07-10
3 month-44%USD 0.032026-05-20
Year to date-78.8%USD 0.082025-12-29
1 year-82.77%USD 0.102025-08-18
3 year-84.73%USD 0.112023-08-15
5 year-76%USD 0.072021-08-16
Since inception-91.6%USD 0.202019-09-09

Botanix Pharmaceuticals Financials at a Glance

Market Cap

$45.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$23.98M

Net Income (TTM)

-A$127.98M

EPS (TTM)

-$0.02

P/E Ratio

-0.56

Dividend

$0.00

Beta (Volatility)

0.20 (Low)

Price

$0.02

Volume

45,000

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.01 - $0.13

Estimated Earnings Date

Mar 3, 2027

BXPHF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited is a dermatology-focused company dedicated to developing safe and effective topical treatments for serious skin conditions. The product pipeline includes treatments for moderate to severe acne, atopic dermatitis, rosacea, and axillary hyperhidrosis, utilizing a proprietary drug delivery system.

Products and Services
  • Topical treatments for moderate to severe acne
  • Innovative solutions for atopic dermatitis and rosacea
  • Exclusive drug delivery system for skin diseases
Growth Outlook
  • Recent revenue of AUD 16.5 million indicates strong market interest
  • Proprietary technology enhances product efficacy and market potential
  • Expanding product pipeline may lead to increased market share
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 41.5 million
  • Cash and cash equivalents of AUD 31.6 million as of last quarter
  • Current ratio of 2.56 suggests strong liquidity position
Botanix Pharmaceuticals Limited is positioned in the healthcare sector, specifically within the medical pharmaceuticals industry. The company is focused on addressing significant dermatological needs through innovative treatments. The recent revenue growth reflects a positive reception in the market, while the proprietary drug delivery system enhances the potential for effective treatment options. With a solid cash position, the company is well-equipped to support ongoing research and development efforts. The current ratio indicates a favorable liquidity position, allowing for operational flexibility. Overall, Botanix Pharmaceuticals presents an intriguing opportunity for investors interested in the dermatology market.
AI Generated • Aug 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Howie McKibbon, PharmD

Website

www.botanixpharma.com

Headquarters

Melbourne, WA 3008, AU

BXPHF Financials

Key Financial Metrics (TTM)

Gross Margin

-118.23%

Operating Margin

-380.62%

Net Income Margin

-404.72%

Return on Equity

-131.13%

Return on Capital

-76.14%

Return on Assets

-89.99%

Earnings Yield

-1.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$45.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.74B

Volume

45.00K

Avg. Volume

12.11K

Financials (TTM)

Gross Profit

-A$27.72M

Operating Income

-A$123.23M

EBITDA

-A$121.47M

Operating Cash Flow

-A$115.58M

Capital Expenditure

-A$365.23K

Free Cash Flow

-A$115.94M

Cash & ST Invst.

A$31.60M

Total Debt

A$30.04M

Botanix Pharmaceuticals Performance Analysis

Botanix Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 615,506N/A
20242024-06-30AUD 678,02310.2%
20252025-06-30AUD 4,198,478519.2%
Botanix Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30347.6%
Q22024-12-31-77.7%
Q42025-06-301333.2%
Q22025-12-31204.9%
Botanix Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.01N/A
20232023-06-30AUD -0.01-45.9%
20242024-06-30AUD -0.0115.1%
20252025-06-30AUD -0.03396.7%
Botanix Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-42.1%
Q22024-12-31-214.8%
Q42025-06-30-74.1%
Q22025-12-3142.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$16.50M

+4265.7%

Gross Profit

-A$28.75M

-850.5%

Gross Margin

-1.74%

N/A

Market Cap

$45.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.18M

N/A

Employees

11

N/A

Net Income

-A$33.18M

-506.9%

EBITDA

-A$32.42M

-1075.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$31.60M

+72.6%

Total Debt

A$30.04M

N/A

Accounts Receivable

A$5.70M

+2496.0%

Inventory

A$27.50M

+778.0%

Long Term Debt

A$16.91M

N/A

Short Term Debt

A$13.13M

N/A

Return on Assets

-89.99%

N/A

Return on Invested Capital

-1.18%

N/A

Free Cash Flow

-A$32.63M

-76.0%

Operating Cash Flow

-A$32.63M

-767.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NDTPNDT Pharmaceuticals Inc.
$0.51+0.00%
JWCTFJW (Cayman) Therapeutics Co. Ltd
$0.20+0.00%
AAWHAscend Wellness Holdings, Inc.
$0.43-3.43%
SCNLFScancell Holdings plc
$0.14+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$209.66-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.87-0.02%
BITOProShares Trust - ProShares Bitcoin ETF
$10.58-0.01%
INTCIntel
$88.24+0.01%

Questions About BXPHF

What is the current price of Botanix Pharmaceuticals?

Botanix Pharmaceuticals is trading at $0.02 per share.

What is the 52-week range for Botanix Pharmaceuticals?

Over the past 52 weeks, Botanix Pharmaceuticals has traded between $0.01 and $0.13.

How much debt does Botanix Pharmaceuticals have?

As of the most recent reporting period, Botanix Pharmaceuticals reported total debt of A$21.04M.

How much cash does Botanix Pharmaceuticals have on hand?

Botanix Pharmaceuticals reported A$42.58M in cash and cash equivalents in its most recent financial results.

What is Botanix Pharmaceuticals’s dividend yield?

Botanix Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services